Alamar Biosciences launches national blood biomarker initiative for Alzheimer’s research

Alamar Biosciences, Inc.

Alamar Biosciences, Inc.

ALMR

0.00
  • Alamar Biosciences launched a national proteomics initiative with leading universities to advance blood-based biomarkers for Alzheimer’s and related dementias.
  • Project targets about 21,000 plasma samples from 10,000 ADRC participants using the NULISAseq Neuro 220 panel with an added eMTBR-Tau assay.
  • Dataset will be made public, linked to NACC IDs, enabling integration with longitudinal clinical data for AI-driven discovery.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alamar Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607130230OMX_____CNEWS_EN_GNW9760858_en) on July 13, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.